|
|
||||||||||
|
J Am Coll Cardiol, 2007; 50:607-613, doi:10.1016/j.jacc.2007.05.014
(Published online 29 July 2007). © 2007 by the American College of Cardiology Foundation |
,1
,1,2
,1
* Department of Medicine and Laboratory Medicine, Massachusetts General Hospital, Boston, Massachusetts
Department of Emergency Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
Department of Medicine, University of California, San Diego, California
# Department of Laboratory Medicine, University of California, San Francisco, California
Department of Medicine, Virginia Commonwealth University, Richmond, Virginia
|| Department of Medicine, University Hospital Maastricht, Maastricht, the Netherlands
¶ Department of Preventive Medicine and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Manuscript received February 12, 2007; revised manuscript received May 8, 2007, accepted May 9, 2007.
* Reprint requests and correspondence: Dr. James L. Januzzi, Jr., Massachusetts General Hospital, Yawkey 5984, 55 Fruit Street, Boston, Massachusetts 02114. (Email: JJanuzzi{at}Partners.org).
Objectives: The aim of this study was to examine the value of measurement of the interleukin-1 receptor family member ST2 in patients with dyspnea.
Background: Concentrations of ST2 have been reported to be elevated in patients with heart failure (HF).
Methods: Five hundred ninety-three dyspneic patients with and without acute destabilized HF presenting to an urban emergency department were evaluated with measurements of ST2 concentrations. Independent predictors of death at 1 year were identified.
Results: Concentrations of ST2 were higher among those with acute HF compared with those without (0.50 vs. 0.15 ng/ml; p < 0.001), although amino-terminal pro-brain natriuretic peptide (NT-proBNP) was superior to ST2 for diagnosis of acute HF. Median concentrations of ST2 at presentation to the emergency department were higher among decedents than survivors at 1 year (1.08 vs. 0.18 ng/ml; p < 0.001), and in multivariable analyses, an ST2 concentration
0.20 ng/ml strongly predicted death at 1 year in dyspneic patients as a whole (HR = 5.6, 95% confidence interval [CI] 2.2 to 14.2; p < 0.001) as well as those with acute HF (hazard ratio [HR] = 9.3, 95% CI 1.3 to 17.8; p = 0.03). This risk associated with an elevated ST2 in dyspneic patients with and without HF appeared early and was sustained at 1 year after presentation (log-rank p value <0.001). A multi-marker approach with both ST2 and NT-proBNP levels identified subjects with the highest risk for death.
Conclusions: Among dyspneic patients with and without acute HF, ST2 concentrations are strongly predictive of mortality at 1 year and might be useful for prognostication when used alone or together with NT-proBNP.
| ||||||||||||
This article has been cited by other articles:
![]() |
E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF] |
||||
![]() |
T. Mueller, B. Dieplinger, A. Gegenhuber, W. Poelz, R. Pacher, and M. Haltmayer Increased Plasma Concentrations of Soluble ST2 are Predictive for 1-Year Mortality in Patients with Acute Destabilized Heart Failure Clin. Chem., April 1, 2008; 54(4): 752 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2344 - 2351. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |